<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04537390</url>
  </required_header>
  <id_info>
    <org_study_id>2016-610</org_study_id>
    <nct_id>NCT04537390</nct_id>
  </id_info>
  <brief_title>Anti-mullerian Hormone Levels in Healthy Females</brief_title>
  <acronym>AMH</acronym>
  <official_title>Anti-mullerian Hormone Levels in Healthy Females</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erin Rowell</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ann &amp; Robert H Lurie Children's Hospital of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to have a better understanding of the normal blood levels of AMH&#xD;
      in females from 0-18 years of age and how the blood AMH levels correspond to a female's&#xD;
      reproductive development.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anti-mullerian hormone (AMH) is a chemical in the body that is found in the blood that can&#xD;
      estimate the ability of a female to have her own children. It is widely used in adult female&#xD;
      cancer patients to predict the onset of menopause and/or the inability to have children that&#xD;
      can be associated with chemotherapy and/or radiation treatment. Normal blood levels of AMH&#xD;
      are better understood in adults than in children and adolescents. The purpose of this study&#xD;
      is to have a better understanding of the normal blood levels of AMH in females from 0-18&#xD;
      years of age and how the blood AMH levels correspond to a female's reproductive development.&#xD;
      With a better understanding of normal AMH levels in children, we may be able to better assess&#xD;
      a girl's risk of not being able to have children if she is a cancer patient, and may be able&#xD;
      to offer her and her family options to increase the chances of having her own children.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 19, 2016</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti-mullerian Hormone Levels in Healthy Females</measure>
    <time_frame>3 Years</time_frame>
    <description>The primary outcome measure is to get a better understanding of the normal AMH levels in children (girls aged 0-18 years) in order to better assess a girl's risk of not being able to have children if she is a cancer patient, and in offering her and her family options to increase the chances of having her own children</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Blood sample collection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Blood samples are collected for diagnostically assessing how the blood AMH levels correspond to a female's reproductive development</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood sample collection</intervention_name>
    <description>Blood samples are collected for diagnostically assessing how the blood AMH levels correspond to a female's reproductive development</description>
    <arm_group_label>Blood sample collection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Pre- and post-pubertal females&#xD;
&#xD;
          2. Ages 0-18 years old&#xD;
&#xD;
          3. Tanner Stage I- V&#xD;
&#xD;
          4. Undergoing routine outpatient surgical procedure&#xD;
&#xD;
               1. Hernia repair (inguinal, umbilical, epigastric)&#xD;
&#xD;
               2. Excision of benign mass&#xD;
&#xD;
               3. laparoscopic cholecystectomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous diagnosis of an illness associated with premature ovarian failure (Turner's&#xD;
             syndrome, Fragile X permutation carrier) or endocrine disorder associated with&#xD;
             irregular menstrual cycles (Cushing's disease, poorly-controlled Thyroid disease,&#xD;
             hyperprolactinemia, polycystic ovary syndrome, and congenital adrenal hyperplasia) or&#xD;
             insulin-dependent diabetes mellitus or autoimmune disorders&#xD;
&#xD;
          2. Previous diagnosis of any malignancy or any history of systemic/local chemotherapy,&#xD;
             radiation therapy, or stem-cell transplant.&#xD;
&#xD;
          3. Previous surgical excision of one ovary or both ovaries&#xD;
&#xD;
          4. Pregnant females&#xD;
&#xD;
          5. All inpatient surgical patients&#xD;
&#xD;
          6. Undergoing non-routine outpatient surgical procedures&#xD;
&#xD;
               1. Central venous catheter placement&#xD;
&#xD;
               2. Supprelin insertion/removal&#xD;
&#xD;
               3. Breast mass excision&#xD;
&#xD;
               4. Gastrostomy tube insertion&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Erin Rowell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ann &amp; Robert H Lurie Children's Hospital of Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacquelyn Searcy</last_name>
    <phone>3122274758</phone>
    <email>FertilityPreservationMB@luriechildrens.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ann &amp; Robert H Lurie Children's Hospital of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacquelyn Searcy</last_name>
      <phone>312-227-4758</phone>
      <email>FertilityPreservationMB@luriechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Erin Rowell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 28, 2020</study_first_submitted>
  <study_first_submitted_qc>August 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2020</study_first_posted>
  <last_update_submitted>August 28, 2020</last_update_submitted>
  <last_update_submitted_qc>August 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ann &amp; Robert H Lurie Children's Hospital of Chicago</investigator_affiliation>
    <investigator_full_name>Erin Rowell</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>AMH</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

